Enveda raises $311 million Series E to advance nature-derived AI drugs
Enveda, a biotech startup that applies artificial intelligence to discover medicines from plants and microbes, announced a $311 million Series E financing round. The round was led by Catalio Capital Management with participation from Iconiq and other investors, and values the company at $2 billion, roughly double the valuation it held a year earlier.
Key points
- Enveda secured $311 million in a Series E round led by Catalio Capital Management.
- The financing values Enveda at $2 billion, double its valuation from a year earlier.
- Enveda is testing AI‑discovered drugs for severe skin conditions and post‑GLP‑1 weight‑loss maintenance.
Founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals, Enveda aims to speed up drug discovery by using AI to explore natural product space. While no AI‑discovered drug has yet received FDA approval, Enveda is among the companies moving AI‑identified candidates into human trials. The startup is currently testing several compounds, including one for severe skin conditions and another intended to sustain weight loss after discontinuing GLP‑1 therapies.
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
TechCrunch AI · 23 September 2026
Loading the full article…
This text was published by TechCrunch AI and written by Marina Temkin. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Business & Funding
All →- Microsoft pledges more than $10 billion in cloud and AI investment across Kuwait, Qatar, Saudi Arabia, and UAE by 2030 · 8 src
- Anthropic reportedly delays IPO to November amid safety warnings and market doubts · 8 src
- SoftBank raises over $11 billion in bonds to fund OpenAI investment · 4 src
- OpenAI says Apple's ChatGPT integration underperformed after 2024 launch · 3 src
- Oppenheimer says Microsoft Azure and M365 can sustain acceleration in fiscal 2027 · 6 src
Comments
via GitHub Discussions